Evaluation of Two Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis

Study Title

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Teva Identifier

PM034

ClinicalTrials.gov Identifier

NCT01167426

Study Status

Completed

Trial Condition(s)

Multiple Sclerosis

Interventions

Drug: Glatiramer Acetate 20 mg/0.5 mL | Drug: Glatiramer acetate 20 mg/0.5 mL

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years and older

Trial Duration

07/01/2010 - 12/01/2010

Phase

Phase 3

Study Type

Interventional